Recurrence of Psoriasis Vulgaris Accompanied by Treatment with C-C Chemokine Receptor Type 4 (CCR4) Antibody (Mogamulizumab) Therapies in a Patient with Adult T cell Leukemia/ Lymphoma: Insight into Autoinflammatory Diseases.

Abstract

Adult T cell leukemia / lymphoma (ATL) is one of the most aggressive hematological malignancies caused by human T-lymphotropic virus type-I (HTLV-1). Mogamulizumab is a new defucosylated humanized monoclonal antibody agent which targets C-C chemokine receptor type 4 (CCR4) expressed occasionally on the surface of ATL cells. However, adverse events such as drug eruptions have also been highlighted, at least in part, via the dysfunction of regulatory T cells (Tregs). We herein report a pronounced recurrence of systemic psoriasis vulgaris accompanied by the treatment of mogamulizumab in a patient with ATL. Pathological examinations may suggest a mechanistic link between the recurrence of autoinflammatory diseases and anti-CCR4 antibody therapies.

• Authors: Kazuho Morichika, Takeaki Tomoyose, Taeko Hanashiro, Natsuki Shimabukuro, Keita Tamaki, Iori Tedokon, Yukiko Nishi, Sawako Nakachi, Ken-Nosuke Karube, Takuya Fukushima, Takeharu Katoh, Koichi Ohshima, Hiroaki Masuzaki
• Journal: Internal medicine (Tokyo, Japan) (Intern Med) Vol. 55 Issue 10 Pg. 1345-9 ( 2016) ISSN: 1349-7235 [Electronic] Japan
• PMID: 27181545 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal, Humanized
• mogamulizumab

Topics

• Antibodies, Monoclonal, Humanized (adverse effects, therapeutic use)
• Female
• Human T-lymphotropic virus 1 (immunology)
• Humans
• Leukemia-Lymphoma, Adult T-Cell (drug therapy, therapy)
• Middle Aged
• Psoriasis (chemically induced)
• Recurrence